This study investigates the expression of HER2 and Ki-67 in gastric cancer and their relationship with clinicopathological features, as well as explores the association between these markers and the clinical development and invasiveness of gastric cancer. We conducted a retrospective study involving 118 hospitalized patients with gastric cancer diagnosed by gastroscopic biopsy or pathological examination after gastric cancer surgery at the Fifth Affiliated Hospital of Zhengzhou University from March 2020 to December 2023. Baseline and immunopathological data were collected and analyzed, dividing the patients into low and high expression groups based on Ki-67 expression levels. We examined the relationships between HER2 and Ki-67 expressions and the clinicopathological characteristics of gastric cancer. The results showed that the positive and high expression rate of HER2 in gastric cancer was 13.6% (16/118), while the high expression rate of Ki-67 (>30%) was 78.8% (93/118). HER2 expression was positively correlated with the maximum diameter of gastric cancer (correlation coefficient: 0.182, P = 0.049) and the degree of differentiation of gastric cancer (correlation coefficient: 0.280, P = 0.049). Ki-67 expression showed significant differences related to tumor maximum diameter, stage (early vs. advanced), histological type, location, depth of invasion, lymph node invasion stage, and pTNM stage (P < 0.05). However, there was no significant correlation between HER2 and Ki-67 expressions in gastric cancer patients (r = 0.127, P = 0.171). In summary, the expressions of HER2 and Ki-67 are closely related to the clinicopathological features of gastric cancer. Larger tumor diameter and better differentiation are associated with higher HER2 positive grades, while Ki-67 is closely related to the occurrence, development, and invasiveness of gastric cancer. There is no significant correlation between the expressions of HER2 and Ki-67 in gastric cancer tissues.

Yanya Liu, Xiaomeng Chen, Xinyu Zheng, Chenchen Xie, Wenzhen Wang, Qian Liu, Xingzhou Xia. Expression of HER2 and Ki-67 in gastric cancer and its correlation with clinicopathological features. International Journal of Frontiers in Medicine (2024), Vol. 6, Issue 7: 44-50. https://doi.org/10.25236/IJFM.2024.060708.

[1] Cheng Xiaofen, Min Shuhui, Guo Ruiqi, Zhang Jindan, Li Bei. Age-period-cohort analysis of incidence and mortality of gastric cancer in China from 1990 to 2019 and prediction of trends from 2020 to 2030[J]. Chinese Journal of Oncology, 2023, 06:454-461.

[2] Bang Y J, Van C E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. Lancet, 2010, 376(9742):687-697. DOI:10.1016/S0140-6736(10)61121-X.

[3] Huang Dan, Li Zengshan, Fan Xiangshan, et al. Analysis of HER2 detection results in 40,842 cases of gastric adenocarcinoma in Chinese people [J]. Chinese Journal of Pathology, 2018, 47(11):822-826. DOI:10.3760/cma.j.issn.0529-5807.2018.11.002

[4] Arciero C A. Ki‐67 proliferation index and gastric cancer: Answers or more questions[J]. Journal of Surgical Oncology, 2010, 102(3):199-200. DOI:10.1002/jso.21626.

[5] Huang G, Chen S, Wang D, et al. High Ki-67 Expression has Prognostic Value in Surgically-Resected T3 Gastric Adenocarcinoma[J]. Clinical laboratory, 2016, 62(1-2):141. DOI:10.7754/Clin.Lab. 2015. 150610.

[6] Awadh Mohmmed, Darwish Aysha, Alqatari Huda, Buzaid Fatema M, Darwish Abdulla. A descriptive analysis of gastric cancer with an immunohistochemical Study of Ki-67 and p53 as prognostic factors: Bahrain experience[J]. Saudi medical journal, 2023, 4412.

[7] Dai X, Zhang X, Yu J. Clinicopathological features and Borrmann classification associated with HER2-positive in primary gastric cancer[J]. Clinical and Experimental Gastroenterology, 2019, 12. DOI:10.2147/CEG.S212895.

[8] Yoshiki Kataoka, Hiroshi Okabe, Akihiko Yoshizawa, et al. HER2 expression and its clinicopathological features in resectable gastric cancer [J]. Gastric Cancer, 2013. DOI: 10. 1007/ s10120-012-0150-9.

[9] Luo G, Hu Y, Zhang Z, et al. Clinicopathologic significance and prognostic value of Ki-67 expression in patients with gastric cancer: a meta-analysis[J]. Oncotarget, 2017, 8(30). DOI:10.18632/oncotarget.17305.

[10] Hong-Wen Wu, Cheng-Yong Qin, Ji-Lai Huang, et al. Correlations of β-catenin, Ki-67 and Her-2/neu with gastric cancer[J]. Asian Pacific Journal of Tropical Medicine, 2014. DOI:CNKI:SUN: YTRY. 0. 2014-04-003.

[11] Cong T D, Thanh T N, Phan Q A N, et al. Correlation between HER2 Expression and Clinicopathological Features of Breast Cancer: A Cross- Sectional Study in Vietnam[J]. Asian Pacific Journal of Cancer Prevention: APJCP, 21(4) [2024-05-01]. DOI:10.31557/APJCP.2020.21.4.1135.